Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18603259 | 1.00 | LMNA (0.55) | LMNAGLATSHRHTR2CFABP7 | |
| SCHEMBL12741664 | 1.00 | LMNA (0.55) | LMNAGLATSHRHTR2CFABP7 | |
| SCHEMBL8466630 | 0.79 | ELANE (0.49) | TSHRFABP7FABP5ELANEALDH1A1 | |
| SCHEMBL16648788 | 0.77 | ALDH1A1 (0.52) | LMNATSHRFABP7FABP5ALDH1A1 | |
| SCHEMBL19749101 | 0.77 | ALDH1A1 (0.52) | LMNATSHRFABP7FABP5ALDH1A1 | |
| SCHEMBL29433900 | 0.77 | ALDH1A1 (0.52) | LMNATSHRFABP7FABP5ALDH1A1 | |
| SCHEMBL20253575 | 0.77 | FABP7 (0.46) | TSHRFABP7FABP5ELANEALDH1A1 | |
| SCHEMBL16938624 | 0.75 | TSHR (0.51) | GLATSHRHTR2CFABP7FABP5 | |
| SCHEMBL5310196 | 0.75 | TSHR (0.51) | GLATSHRHTR2CFABP7FABP5 | |
| Bicarbonate SCHEMBL29739771 | 0.75 | ALDH1A1 (0.50) | LMNATSHRFABP7FABP5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459336-B2 | Pyrazine carbamates and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-04 | — | — | US | disclosed |
| EP-3983072-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| CN-108026080-B | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10590154-B2 | Method for preparing oxazolidinone intermediate | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2020-03-17 | — | — | US | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| EP-3347353-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | LMNA 4827/4885GLA 770/4885TSHR 787/4885 |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | HRH4, HRH3, HRH1 | LMNA 1651/4885GLA 1296/4885TSHR 568/4885 |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | LMNA 2332/4885GLA 1245/4885TSHR 626/4885 |
| US-10590154-B2 | Method for preparing oxazolidinone intermediate | LDHA, SORD, LDHB | LMNA 2369/4885GLA 1672/4885TSHR 3692/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | LMNA 4811/4885GLA 395/4885TSHR 841/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | LMNA 4815/4885GLA 651/4885TSHR 892/4885 |
| US-11459336-B2 | Pyrazine carbamates and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | LMNA 4417/4885GLA 2648/4885TSHR 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.